Oncologic Outcomes of Surgery in T3 Prostate Cancer : Experience of a Single Tertiary Center

Abstract EN

Aim.

The aim of this study is to present the oncologic outcomes and to determine the prognostic factors of overall survival (OS), cancer-specific survival (CSS), disease-progression-free survival (DPFS), and biochemical-progression-free survival (BPFS) after surgery for pT3 prostate cancer (PCa).

Methods.

Between 2002 and 2007, a pT3 stage after radical prostatectomy was detected in 182 patients at our institution.

The Kaplan-Meier analysis was used to calculate OS, CSS, DPFS, and BPFS.

Cox regression was used to identify predictive factors of survival.

Results.

pT3a was detected in 126 (69%) and pT3b in 56 (31%) of cases.

Five-year OS, CSS, DPFS, and BPFS rates were 90.7%, 94%, 91.8%, and 48.4%, respectively.

Survival was significantly different when comparing pT3a to pT3b groups.

The 5-year OS, CSS, DPFS, and BPFS were 96% versus 72%, 98% versus 77%, 97.3% versus 79.3%, and 60% versus 24.2%, respectively.

Specimen Gleason score was the most significant predictor of OS, CSS, DPFS, and BPFS.

The risk of death increased up to 3-fold when a Gleason score 8–10 was present at the final pathology.

Conclusions.

Radical prostatectomy may offer very good CSS, OS, DPFS, and BPFS rates in pT3a PCa.

However, outcomes in patients with pT3b or specimen Gleason ≥8 were significantly worse, suggesting the need for multimodality treatment in those cases.